RLAY - CIK 0001812364
Relay Therapeutics, Inc. (RLAY) reported net income of -$276.48M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$276.48M | +18.1% |
| FY 2024 | -$337.71M | +1.2% |
| FY 2023 | -$341.97M | -17.7% |
| FY 2022 | -$290.51M | +20.2% |
| FY 2021 | -$363.87M | -594.3% |
| FY 2020 | -$52.41M | +30.4% |
| FY 2019 | -$75.31M | - |
Relay Therapeutics, Inc. (RLAY) reported net income of -$276.48M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, Relay Therapeutics, Inc.'s net income declined from -$75.31M to -$276.48M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.